EUVIMEDEUVIMED entdecken
Crossref

Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022

Patricia Mae G Santos, Lillian A Boe, Kawther Al Ksir, Ticiana Leal, Daniel R Gomez, Ravi B Parikh

Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)

DOI: 10.6004/jnccn.2026.7043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-11. Verfasst von Patricia Mae G Santos und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Health Services, Outcomes, and Policy, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Nearly half of patients with advanced non–small cell lung cancer (aNSCLC) have actionable mutations that can be detected through broad-based genomic sequencing (BGS) or focused biomarker testing (FBT). Although national guidelines advocate for early BGS, its impact on survival in the era of targeted therapy remains unclear. This study evaluates whether BGS is associated with improved progression-free survival (PFS) and overall survival (OS) compared with FBT. Patients and Methods: This retrospective cohort study used electronic health record data from the Flatiron Health Research Database (2016–2022), which includes data from approximately 280 US academic and community oncology clinics. Adults (age ≥18 years) with stage IIIB–IV NSCLC who received at least one line of systemic therapy were included. Patients were categorized based on receipt of BGS or FBT

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansFemaleRetrospective StudiesMaleAgedMiddle AgedNeoplasm StagingMutationGenomics

Stichwörter der Autor:innen

Next-generation sequencingTargeted Therapynon-small cell lung cancerreal-world data

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • 1Division of Health Services, Outcomes, and Policy, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA.
  • 2Department of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA.
  • 3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • 4Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
  • 5Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

Zitieren

APA

Santos, P. M. G., Boe, L. A., Al Ksir, K., Leal, T., Gomez, D. R., & Parikh, R. B. (2026). Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022. Journal of the National Comprehensive Cancer Network, 24(11). https://doi.org/10.6004/jnccn.2026.7043

Vancouver

Santos PMG, Boe LA, Al Ksir K, Leal T, Gomez DR, Parikh RB. Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022. Journal of the National Comprehensive Cancer Network. 2026;24(11). doi:10.6004/jnccn.2026.7043

BibTeX
@article{Santos2026,
  author = {Santos, Patricia Mae G and Boe, Lillian A and Al Ksir, Kawther and Leal, Ticiana and Gomez, Daniel R and Parikh, Ravi B},
  title = {Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {11},
  doi = {10.6004/jnccn.2026.7043}
}
Kostenlos starten →